Chu Chung-Ming, Chan Veronica L, Wong Ida W Y, Leung Wah-Shing, Lin Alsa W N, Cheung King-Fai
Department of Medicine and Geriatrics, United Christian Hospital, Kowloon, Hong Kong, SAR, China.
Crit Care Med. 2004 Feb;32(2):372-7. doi: 10.1097/01.CCM.0000108879.86838.4F.
To determine the long-term outcome of noninvasive ventilation in chronic obstructive pulmonary disease patients who refused intubation for acute hypercapnic respiratory failure.
Prospective, observational study.
Noninvasive ventilation unit in an acute regional hospital in Hong Kong.
The study recruited 37 chronic obstructive pulmonary disease patients who had the do-not-intubate code and developed acute hypercapnic respiratory failure. They were offered noninvasive ventilation, and their long-term outcomes were followed. Survival and event-free survival (an event is death or recurrent acute hypercapnic respiratory failure) were analyzed by survival analysis. Their disease profile and outcome were compared with another 43 chronic obstructive pulmonary disease patients without the do-not-intubate codes, who had acute hypercapnic respiratory failure and received noninvasive ventilation during the study period (usual care group).
Patients in the do-not-intubate group were significantly older (p =.029), had worse dyspnea score (p <.001), worse Katz Activities of Daily Living score (p <.001), worse comorbidity score (p =.024), worse Acute Physiology and Chronic Health Evaluation II score (p =.032), lower hemoglobin (p =.001), and longer stay in the hospital during the past year (p =.001) than patients who received usual care. In the do-not-intubate group, the median survival was 179 days, and 1-yr actuarial survival was 29.7%; in the usual care group, the median survival was not reached during follow-up, and 1-yr actuarial survival was 65.1% (p <.0001). In the do-not-intubate group, the median event-free survival was 102 days, and 1-yr event-free survival was 16.2%; in the usual care group, median event-free survival was 292 days, and 1-yr event-free survival was 46.5% (p =.0004).
A 1-yr survival of about 30% was recorded in chronic obstructive pulmonary disease patients with the do-not-intubate code who developed acute hypercapnic respiratory failure requiring noninvasive ventilation. The majority of survivors developed another life-threatening event in the following year. Information generated from this study is important to physicians and chronic obstructive pulmonary disease patients when they are considering using noninvasive ventilation as a last resort.
确定拒绝因急性高碳酸血症呼吸衰竭而行气管插管的慢性阻塞性肺疾病患者无创通气的长期预后。
前瞻性观察性研究。
香港一家急性区域医院的无创通气病房。
本研究纳入了37例有“不要插管”医嘱且发生急性高碳酸血症呼吸衰竭的慢性阻塞性肺疾病患者。为他们提供无创通气,并对其长期预后进行随访。通过生存分析评估生存情况和无事件生存情况(事件定义为死亡或复发性急性高碳酸血症呼吸衰竭)。将他们的疾病情况和预后与另外43例没有“不要插管”医嘱、发生急性高碳酸血症呼吸衰竭且在研究期间接受无创通气的慢性阻塞性肺疾病患者(常规治疗组)进行比较。
“不要插管”组患者的年龄显著更大(p = 0.029),呼吸困难评分更差(p < 0.001),Katz日常生活活动评分更差(p < 0.001),合并症评分更差(p = 0.024),急性生理与慢性健康状况评估II评分更差(p = 0.032),血红蛋白水平更低(p = 0.001),且过去一年的住院时间更长(p = 0.001)。在“不要插管”组中,中位生存期为179天,1年精算生存率为29.7%;在常规治疗组中,随访期间未达到中位生存期,1年精算生存率为65.1%(p < 0.0001)。在“不要插管”组中,中位无事件生存期为102天,1年无事件生存率为16.2%;在常规治疗组中,中位无事件生存期为292天,1年无事件生存率为46.5%(p = 0.0004)。
有“不要插管”医嘱且发生需要无创通气的急性高碳酸血症呼吸衰竭的慢性阻塞性肺疾病患者,1年生存率约为30%。大多数幸存者在次年发生了另一次危及生命的事件。本研究得出的信息对于医生和慢性阻塞性肺疾病患者在考虑将无创通气作为最后手段时具有重要意义。